1. Home
  2. CACI vs NUVL Comparison

CACI vs NUVL Comparison

Compare CACI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CACI International Inc.

CACI

CACI International Inc.

HOLD

Current Price

$525.60

Market Cap

11.6B

Sector

Technology

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.39

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CACI
NUVL
Founded
1962
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6B
9.8B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
CACI
NUVL
Price
$525.60
$123.39
Analyst Decision
Buy
Strong Buy
Analyst Count
12
16
Target Price
$689.50
$134.75
AVG Volume (30 Days)
252.7K
2.7M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
17.11
N/A
Revenue
$4,467,860,000.00
N/A
Revenue This Year
$12.42
N/A
Revenue Next Year
$10.00
$1,239.49
P/E Ratio
$30.46
N/A
Revenue Growth
2.60
N/A
52 Week Low
$439.67
$71.14
52 Week High
$683.50
$123.62

Technical Indicators

Market Signals
Indicator
CACI
NUVL
Relative Strength Index (RSI) 55.95 66.62
Support Level $490.31 $97.71
Resistance Level $539.13 N/A
Average True Range (ATR) 18.64 4.24
MACD 2.60 2.74
Stochastic Oscillator 69.23 99.49

Price Performance

Historical Comparison
CACI
NUVL

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: